For decades, older Americans enrolled in Medicare faced a simple reality when it came to obesity medications: federal law said no. Weight loss drugs were explicitly excluded from Medicare Part D coverage, the portion of the program that handles prescription drug costs. If a Medicare beneficiary wanted access to one of the newer weight loss medications and did not have a qualifying condition like type 2 diabetes, they were on their own. Retail prices for these drugs run between roughly $1,271 and $1,646 per month, a cost that is simply out of reach for most people living on a fixed income.
That changes shortly. Starting July 1st, the Centers for Medicare and Medicaid Services (CMS) launched a short-term demonstration called the Medicare GLP-1 Bridge, which will provide eligible Medicare Part D beneficiaries with access to certain GLP-1 drugs. The program is set to run through December 31, 2027, and eligible beneficiaries will pay a flat $50 monthly copay.
GLP-1 stands for glucagon-like peptide-1, a hormone that the body naturally produces to regulate appetite and blood sugar. The drugs work by mimicking that hormone, helping people feel full sooner and reducing food cravings. These medications have grown considerably in popularity in recent years due to their demonstrated effectiveness. The problem was not their efficacy but who could afford them.
Under federal law, Medicare Part D plans cannot cover medications prescribed for weight loss. Changing the law to permit Medicare Part D plans to cover weight loss medications would require Congress to act. CMS found a workaround by using its authority to run demonstration programs, which allow it to test changes to payment and coverage methods without requiring new legislation. The Bridge program operates entirely outside of the standard Part D benefit, meaning a patient’s existing drug plan does not need to opt in for the coverage to apply.
Three specific medications are covered under the program when prescribed for weight management: Foundayo, Wegovy (both injectable and tablet forms), and the KwikPen formulation of Zepbound. Foundayo is an oral pill developed by Eli Lilly (NYSE: LLY), while Wegovy is manufactured by Novo Nordisk (NYSE: NVO) and Zepbound is also an Eli Lilly product. The oral option is particularly notable for older adults who may prefer not to use injections.
To qualify, a patient must meet specific clinical criteria. Beneficiaries must have obesity or be overweight, and must also have been diagnosed with certain health conditions such as uncontrolled hypertension. More specifically, patients with a BMI of 35 or higher qualify on their own, while those with a lower BMI may qualify if they have a condition such as prediabetes, heart failure, chronic kidney disease, or a history of heart attack or stroke. Beneficiaries who already receive GLP-1 coverage through Part D for conditions like type 2 diabetes or sleep apnea are not eligible for the Bridge, since those conditions already have a coverage pathway.
The scale of who could benefit is substantial. More than 56 million Americans have Medicare Part D, according to CMS. With nearly 40% of Americans over 65 having obesity, that translates to as many as 22 million people who may be able to take part in the program, depending on their weight and health. A previous KFF analysis estimated that close to 14 million Medicare beneficiaries had a diagnosis of overweight or obesity, suggesting the eligible pool, while large, will depend heavily on individual clinical criteria being met.
Participating manufacturers have agreed to provide GLP-1 medications at a reduced net price of approximately $245 per month, with eligible beneficiaries generally paying about $50 for a monthly prescription. That is a meaningful reduction compared to full retail pricing, which for Wegovy alone can reach approximately $1,646 per month according to GoodRx pricing data.
The Bridge program was originally connected to a longer-term initiative called the BALANCE Model, which was designed to eventually bring GLP-1 obesity coverage into the standard Part D benefit. In May 2026, CMS announced that the Part D portion of the BALANCE Model will be delayed indefinitely, and that the GLP-1 Bridge will be extended through December 31, 2027. That delay introduces some uncertainty about what happens to patients after the Bridge period ends, though CMS has indicated it will use the data gathered to inform future coverage decisions.
What is clear is that this program is not a permanent fix. It is a test, and a time-limited one at that. But for the millions of older adults who have watched these drugs transform weight management for others while remaining financially out of reach, the Bridge program represents the first concrete federal step toward changing that reality.
